Combined blockade of IL-6 and PD-L1 inhibits pancreatic cancer progression and prolongs survival by increasing the infiltration of intratumoral effector CD8+ T cells and promoting the conversion of circulating CD4+ T cells to the Th1 phenotype. The gene discussed is CD8A; the disease is pancreatic neoplasm.